万孚生物收盘上涨2.22%，滚动市盈率22.09倍，总市值117.61亿元

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Wanfu Biological, indicating a decline in revenue and net profit in the first quarter of 2025 compared to the previous year [1][2] - As of August 7, Wanfu Biological's stock closed at 24.43 yuan, with a rolling PE ratio of 22.09, marking a new low in 11 days, and a total market capitalization of 11.761 billion yuan [1] - The company operates in the medical device industry, which has an average PE ratio of 54.79, with Wanfu Biological ranking 49th among its peers [1][2] Group 2 - For the first quarter of 2025, Wanfu Biological reported an operating income of 800 million yuan, a year-on-year decrease of 7.06%, and a net profit of 189 million yuan, down 13.37% year-on-year, with a gross profit margin of 66.67% [2] - The company has received numerous accolades, including being recognized as a national high-tech enterprise and a national-level "green factory" [1] - Wanfu Biological specializes in the research, production, and marketing of rapid diagnostic reagents and related instruments, focusing on infectious disease testing, chronic disease testing, pregnancy and reproductive health testing, and drug abuse testing [1]